To test the impact of capivasertib on CAR T cell antitumor activity, we used CD19-CAR T cells that were generated with 0.25 μM capivasertib treatment (short or long term) in our mantle cell lymphoma JeKo-1 xenograft model (Figure 2A). Here, CD19 is linked to mantle cell lymphoma.